1
|
Saidoune F, Lee D, Di Domizio J, Le Floc’h C, Jenelten R, Le Pen J, Bondet V, Joncic A, Morren MA, Béziat V, Zhang SY, Jouanguy E, Duffy D, Rice CM, Conrad C, Fellay J, Casanova JL, Gilliet M, Yatim A. Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. J Exp Med 2025; 222:e20231467. [PMID: 40227192 PMCID: PMC11995862 DOI: 10.1084/jem.20231467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 01/02/2025] [Accepted: 02/28/2025] [Indexed: 04/15/2025] Open
Abstract
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protective immunity against SARS-CoV-2 and the association of chilblains with inherited type I interferonopathies, we hypothesized that excessive I-IFN responses to SARS-CoV-2 might underlie the occurrence of chilblains in this context. We identified a transient I-IFN signature in chilblain lesions, accompanied by an acral infiltration of activated plasmacytoid dendritic cells (pDCs). Patients with chilblains were otherwise asymptomatic or had mild disease without seroconversion. Their leukocytes produced abnormally high levels of I-IFN upon TLR7 stimulation with agonists or ssRNA viruses-particularly SARS-CoV-2-but not with DNA agonists of TLR9 or the dsDNA virus HSV-1. Moreover, the patients' pDCs displayed cell-intrinsic hyperresponsiveness to TLR7 stimulation regardless of TLR7 levels. Inherited TLR7 or I-IFN deficiency confers a predisposition to life-threatening COVID-19. Conversely, our findings suggest that enhanced TLR7 activity in predisposed individuals could confer innate, pDC-mediated, sterilizing immunity to SARS-CoV-2 infection, with I-IFN-driven chilblains as a trade-off.
Collapse
Affiliation(s)
- Fanny Saidoune
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Danyel Lee
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| | - Jeremy Di Domizio
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Corentin Le Floc’h
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| | - Raphael Jenelten
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jérémie Le Pen
- Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA
| | - Vincent Bondet
- Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Ana Joncic
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Marie-Anne Morren
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Vivien Béziat
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| | - Shen-Ying Zhang
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| | - Emmanuelle Jouanguy
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| | - Darragh Duffy
- Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Charles M. Rice
- Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA
| | - Curdin Conrad
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jacques Fellay
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jean-Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
- Department of Pediatrics, Necker Hospital for Sick Children, Paris, France
- Howard Hughes Medical Institute, New York, NY, USA
| | - Michel Gilliet
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Ahmad Yatim
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
- Imagine Institute, Paris Cité University, Paris, France
| |
Collapse
|
2
|
Wang J, Liu H. The Roles of Junctional Adhesion Molecules (JAMs) in Cell Migration. Front Cell Dev Biol 2022; 10:843671. [PMID: 35356274 PMCID: PMC8959349 DOI: 10.3389/fcell.2022.843671] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Accepted: 02/10/2022] [Indexed: 01/15/2023] Open
Abstract
The review briefly summarizes the role of the family of adhesion molecules, JAMs (junctional adhesion molecules), in various cell migration, covering germ cells, epithelial cells, endothelial cells, several leukocytes, and different cancer cells. These functions affect multiple diseases, including reproductive diseases, inflammation-related diseases, cardiovascular diseases, and cancers. JAMs bind to both similar and dissimilar proteins and take both similar and dissimilar effects on different cells. Concluding relevant results provides a reference to further research.
Collapse
Affiliation(s)
- Junqi Wang
- Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China
| | - Han Liu
- Department of Pharmacy, People’s Hospital of Longhua, Shenzhen, China
- *Correspondence: Han Liu,
| |
Collapse
|
3
|
Aref S, Al Agdar M, Ramez A, Abou Zeid T, Sabry M, Khaled N. Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia. Asian Pac J Cancer Prev 2021; 22:767-774. [PMID: 33773540 PMCID: PMC8286679 DOI: 10.31557/apjcp.2021.22.3.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Indexed: 11/27/2022] Open
Abstract
Objectives: This study aimed to assess the prognostic value of cortactin and HS1 genes expression in adult B-cell acute lymphoblastic leukemia. Methods: The study included a cohort of 74 adult B-ALL patients and 76 controls. Cortactin and HS1 genes expression were quantified by real time PCR. Results: The expression of cortactin and HS1 were significantly higher in B-ALL patients at diagnosis as compared to post induction levels (P<0.001) as well as normal controls (P<0.001 for all). Cox regression analysis revealed that B-ALL patients with high Cortactin expression as well as high HS1 expression had significant high risk of relapse (P=0.005; Odds ratio (OR)= 1.428, CI= [1.175-1.783]; and P=0.003; OR= 1.078, CI= [1.025-1.134]; respectively) and higher probability of deaths (P= 0.041; OR=1.092, CI =[1.002-1.04]; and P=0.005; OR=1.071, CI=[1.013-1,041]; respectively). Survival analysis revealed that B-ALL patients with high cortactin and high HS1 expression had significantly shorter OS and increased frequency of relapse as compared to those with lower expression levels (P <0.01 for all). Conclusion: High cortactin and HS1 genes expression at diagnosis denote bad clinical outcome in B-ALL patients. Assessment of correction expression at B-ALL diagnosis could be considered as risk biomarker at diagnosis.
Collapse
Affiliation(s)
- Salah Aref
- Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt
| | - Mohamed Al Agdar
- Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt
| | - Ahmed Ramez
- Medical Oncology Unit, Mansoura University Oncology Center (MUOC) Mansoura University, Egypt
| | - Tarek Abou Zeid
- Hematology Unit, Mansoura University Oncology Center (MUOC), Mansoura University, Egypt
| | - Mohamed Sabry
- Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt
| | - Nada Khaled
- Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt
| |
Collapse
|